Dectomax-CA1 receives conditional approval to help protect livestock from a serious parasitic threat while data collection continues.
The U.S. Food and Drug Administration (FDA) has conditionally approved Dectomax-CA1 (doramectin injection) for use in cattle to prevent and treat New World screwworm infestations, marking the first approval of its kind in the U.S. The approval allows immediate use of the drug while additional data is collected for full authorization.
“We understand the urgency with which America’s farmers and ranchers are asking for tools to fight New World screwworm,” said FDA Commissioner Marty Makary. “Today’s conditional approval – the first in the U.S. for NWS – shows our dedication to rapidly advancing important animal medicines when they are needed most. We continue to work tirelessly to complete review of other NWS products to protect multiple animal species in the U.S.”
Manufactured by Zoetis in Kalamazoo, Michigan, Dectomax-CA1 shares the same active ingredient as the previously approved Dectomax product for parasites in cattle and swine.
As the Lord Leads, Pray with Us…
- For Commissioner Makary to seek God’s leading as he oversees the Food and Drug Administration.
- For FDA researchers to be prudent in their testing of medications to treat cattle and livestock.
- For American farmers and ranchers as they seek to prevent the spread of the parasite.
Sources: Food and Drug Administration
